Clinical Trial Search

Primary: Change From Baseline in MADRS Total Score After 6 Weeks of Treatment — -14.50; -20.40; -20.20; -20.92 units on a scale — p=<0.0001

Primary: Mean Belatacept Serum Concentrations Between Weeks 12 and 16 by Nominal Collection Time, Following 10mg/kg IV Belatacept - Pharmacokinetic Population — 8491.00; 242667…

Primary: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion — 22; 19 participants — p=0.28

Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants

Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants

Primary: Number of Participants With Overall Response (OR), as Assessed by the Investigator — 19; 6; 2; 2 Participants

Primary: Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab — 58000; 62300 ng*hr/mL

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants

Primary: Morning Peak Expiratory Flow (mPEF) — 346.42; 362.54; 352.87; 329.75 L/min

Primary: Change in Diameter of the Internal Cervical os From Baseline (Pre-treatment) to Just Prior to the Hysteroscopy Procedure (Post-treatment). — 2.2; 2.3; 1.5 mm

Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent…

Primary: 2-Month Cumulative Incidence of VTE — 5.6; 27.2; 7.2 percent probability — p=0.06

Primary: To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. — 95.9; 83.7 percentage of all subjects vaccinated

Primary: Objective Tumor Response — 0 participants